Innoviva earnings were $127.3M for the trailing 12 months ending Sep 30, 2025, with 87.1% growth year over year. The latest INVA earnings report on Sep 30, 2025 announced Q3 2025 earnings of $89.9M, up 41.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, INVA reported annual earnings of $23.4M, with -87% growth.
INVA past earnings growth
How has INVA's earnings growth performed historically?
On INVA's earnings call on Invalid Date, Innoviva (NASDAQ: INVA) reported Q3 2025 earnings per share (EPS) of $1.30, up 6,400% year over year. Total INVA earnings for the quarter were $89.91 million. In the same quarter last year, Innoviva's earnings per share (EPS) was $0.02.
As of the last Innoviva earnings report, Innoviva is currently profitable. Innoviva's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $127.34 million, a 97.15% increase year over year.
What was INVA's earnings growth in the past year?
As of Innoviva's earnings date in Invalid Date, Innoviva's earnings has grown 87.13% year over year. This is 23.08 percentage points higher than the US Biotechnology industry earnings growth rate of 64.05%. INVA earnings in the past year totalled $127.34 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.